A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)
A Dose Escalation Study of Intranasal Neuropeptide Y in PTSD
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women, age 18-60.
- Participants must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign a written informed consent document. We determine whether they have a sufficient understanding of the study procedures and risks by asking them to explain what's involved in the study and to give examples of study risks and benefits.
- Participants must fulfill DSM-IV criteria for current PTSD, based on the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and on the Clinician-Administered PTSD Scale (CAPS).
- CAPS score must be at least 40 (moderate PTSD severity) at screening.
Exclusion Criteria:
- Current, primary Axis I disorders other than PTSD.
- History or current bipolar disorder or primary psychotic disorders (e.g. schizophrenia, schizoaffective disorder).
- Current diagnosis of anorexia nervosa or bulimia nervosa.
- Women who are pregnant or are breast-feeding.
- Drug or alcohol abuse or dependence within the preceding 3 months.
- poorly controlled hypertension (manifest by SBP > 140 and/or DBP > 90); HR < 60 or > 100 at rest at the time of screening and confirmed immediately prior to randomization
- Evidence of coronary artery disease as evidenced by history, abnormal ECG, typical symptoms
- History of arrhythmia, cardiac surgery, or family history of sudden death
- Hepatic dysfunction as defined by AST and ALT > 2x URL, or alkaline phosphatase and bilirubin > 1.5 x URL within X days prior to randomization
- Chronic renal disease as defined by serum creatinine > 1.9
- Any other serious or unstable clinically significant abnormal findings of laboratory parameters, physical examination, or ECG as determined by the PI.
- Any other serious or unstable condition that would put the subjects at undue risk as determined by the PI or additional safety monitor.
- Serious and imminent suicidal or homicidal risk.
- Psychotropic medication that will not be tapered off at least 7 days prior to screening; withdrawal symptoms must be absent at the time of screening
- History of nasal disorders or sinonasal surgery, or significant nasal abnormalities based on nasal exam.
- Received investigational intervention within 30 days prior to randomization
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: NPY/placebo
This arm gets NPY first then placebo (saline).
The placebo is 0.9% USP-grade saline without NPY.
|
Intranasal administration will be administered with a nasal drug delivery device.
Other Names:
|
|
EXPERIMENTAL: placebo/NPY
This arm gets placebo (saline) first then NPY.
|
Intranasal administration will be administered with a nasal drug delivery device.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Rated Inventory of Side Effects (PRISE)
Time Frame: baseline and within 2 hours of administration of NPY
|
Clinician-administered and safety measures will take place right before and after the administration to identify and evaluate the tolerability of each possible symptom (from baseline to within 2 hours of NPY administration).
|
baseline and within 2 hours of administration of NPY
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
State-Trait Anxiety Inventory (STAI)
Time Frame: baseline and within 2 hours of administration of NPY
|
Self-report behavioral measures will take place right before and after the administration to evaluate acute anxiolytic effects of intranasal administration of NPY
|
baseline and within 2 hours of administration of NPY
|
|
Change in Beck Anxiety Inventory (BAI)
Time Frame: at baseline and within 2 hours of administration of NPY
|
Self-report behavioral measures will take place right before and after the administration to evaluate acute anxiolytic effects of intranasal administration of NPY
|
at baseline and within 2 hours of administration of NPY
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GCO 11-1487
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.